Sun Pharmaceutical Industries secured FDA approval for a generic medication under ANDA205634, a development expected to strengthen the company’s competitive positioning and drive future revenue growth in this specific therapeutic segment. Market analysts view this clearance as a positive catalyst that will likely expand the company's sales potential as the product prepares for commercial launch.